Fig 1.

Dynamics of JAK2^V617F mutational burden during lenalidomide and prednisone therapy. JAK2^V617F mutational burden was measured by a quantitative pyrosequencing assay in bone marrow specimens at the time points specified during lenalidomide and prednisone therapy in the (A) whole cohort of patients, in (B) responders, and in (C) nonresponders. A significant reduction in JAK2^V617F allele burden was observed over the baseline median value after 18 months of therapy in responders (P = .03). In contrast, no reduction in JAK2^V617F allele burden was observed among nonresponders during therapy with lenalidomide and prednisone. Minimum and maximum values at each time point are depicted; median values are depicted within each column.